Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: ggamer who wrote (331)	10/3/2007 1:13:20 PM
From: Keith Feral	Read Replies (1) \| Respond to of 418

There is nothing different about the phase 3 bolus trial than last week. I'm not sure where the phase 2 b trials were heading, given the limitations of infusional 5FU and leucovorin in monotherapy. It's easy to say the trial was a waste of time, now that it's over. There was no folate effect during the infusional delivery of leucovorin or cofactor. Bolus Cofactor works better than infusional Cofactor or infusional leucovorin, measured by the higher efficacy results with no toxicity. From what the company said on the CC, the method of administration caused the difference in the results. They have to demonstrate that bolus Cofactor is the superior method of administration. Obviously, I hope things work out with the marketing partners very soon. I can't imagine that anyone is going to be shocked by the poor performance of the infusional trial once they look at the results. Cofactor doesn't make any sense in an infusional administration if the folate effect is not working. It seems like there were some other issues they had with the underlying disease causing the side effects. I'm not really sure where they are going with that line of thought. However, Merritt kept talking about the different results stemming from the tumor, not the 5FU toxicity.